Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Sulindac 4Biopsy 4Carboplatin 3Vaginal Smears 2Cyclophosphamide 2Colposcopy 2Aspirin 2tanespimycin 1sargramostim 1pirfenidone 1fludarabine phosphate 1alethine 1Radiotherapy 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Papanicolaou Test 1Mycophenolic Acid 1Microarray Analysis 1Lovastatin 1Interleukin-12 Subunit p35 1Interferon-alpha 1Inositol 1Ifosfamide 1Genetic Linkage 1Gene Expression Profiling 1Fluorophotometry 1FANG vaccine 1Erlotinib Hydrochloride 1Endoscopy, Digestive System 1Endoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Precancerous Conditions × alethine × Clear all
NCT00006466 2013-12-18

Beta Alethine in Treating Patients With Myeloma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡